{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-045569","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2023-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.773742+00:00","generated_at":"2026-06-07T09:51:14.580512+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BriaCell reports prelim OS up to 2x literature in ADC-refractory breast cancer subset","bullets":["23 heavily pre-treated (median 6 prior therapies) advanced breast cancer patients, all failed ADCs (KADCYLA, ENHERTU, TRODELVY).","Median OS up to twice that reported in comparable studies; 17 of 23 patients remain alive.","Disease control rate of 40% in evaluable patients; PFS similar or better than last regimen in 40%.","No toxicity-related discontinuations and no cases of Interstitial Lung Disease (ILD) with Bria-IMT regimen."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-045569","json":"https://secwatch.observer/filing/0001493152-23-045569.json","markdown":"https://secwatch.observer/filing/0001493152-23-045569.md","text":"https://secwatch.observer/filing/0001493152-23-045569.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223045569/0001493152-23-045569-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223045569/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:51:14.580512+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}